Study purpose
The RAPIDe-3 Study is evaluating the efficacy and safety of an oral study drug, called deucrictibant, compared to a placebo for the on-demand treatment of angioedema attacks in participants with HAE due to C1-esterase inhibitor (C1-INH) deficiency (type 1 or type 2).
Study periods
Participation in the RAPIDe-3 Study will vary in duration based on how long it takes for a participant to experience and treat 2 qualifying HAE attacks with the study drug. This includes a screening period, a Day 1 visit, an attack treatment phase with a follow-up visit for the first qualifying HAE attack, and an end-of-study visit after a second qualifying HAE attack. Participants will have some visits on-site at the study clinic, while other visits may be performed remotely (where applicable and permitted by local regulations).
A few days after each HAE attack is treated with the study drug, participants will be required to take part in an interview conducted by telephone or teleconference (using an online communication platform such as Webex), whichever is more convenient for a participant.
Each interview will last approximately 1 hour.